Drs. Mark Gladwin and Jesus Tejero’s R01 titled, “Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin,” was competitively renewed with annual direct costs of $637,860 by the National Institutes of Health/National Heart, Lung, and Blood...
